

October 15, 2025



## Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- **Rezolute, Inc. (Nasdaq: RZLT)** (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:

**Event:** Maxim Growth Summit

**Date:** October 22-23, 2025

**Event:** Guggenheim 2nd Annual Healthcare Innovation Conference

**Date:** November 10-12, 2025

**Event:** Jefferies London Healthcare Conference

**Date:** November 17-20, 2025

Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Maxim, Guggenheim, and Jefferies representatives.

### About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown meaningful benefit in clinical trials and real-world use for the treatment of both congenital and tumor HI. For more information, visit [www.rezolutebio.com](http://www.rezolutebio.com).

### Rezolute Contacts:

Christen Baglaneas

[cbaglaneas@rezolutebio.com](mailto:cbaglaneas@rezolutebio.com)

508-272-6717

Carrie McKim

[cmckim@rezolutebio.com](mailto:cmckim@rezolutebio.com)

336-608-9706



Source: Rezolute, Inc.